Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001975524 | SCV002247740 | likely benign | Nemaline myopathy 2 | 2023-12-19 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002571300 | SCV003720463 | uncertain significance | Inborn genetic diseases | 2024-11-07 | criteria provided, single submitter | clinical testing | The c.2023A>G (p.K675E) alteration is located in exon 22 (coding exon 20) of the NEB gene. This alteration results from a A to G substitution at nucleotide position 2023, causing the lysine (K) at amino acid position 675 to be replaced by a glutamic acid (E). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Revvity Omics, |
RCV003130645 | SCV003810137 | uncertain significance | not provided | 2021-06-25 | criteria provided, single submitter | clinical testing | |
Gene |
RCV003130645 | SCV005332417 | uncertain significance | not provided | 2023-05-25 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |